Roberto Alejandro Sica
Dr. Sica’s clinical focus has been on chimeric antigen receptor (CAR) T-cell therapies, immunotherapies and allogeneic stem cell transplantation, central nervous system (CNS) lymphomas and HIV, ATLL and gene therapy for malignant and nonmalignant hematologic disorders.
Dr. Sica’s research focuses on novel cellular therapies, allogeneic bone marrow transplantation for malignant and nonmalignant hematologic disorders, and combination immunotherapy and cancer vaccine.
<p>Roberto Alejandro Sica, MD, is an Attending Physician at Montefiore and an Assistant Professor of Medicine at our Albert Einstein College of Medicine. Since joining the Montefiore team, Dr. Sica’s clinical focus has been on chimeric antigen receptor (CAR) T-cell therapies, immunotherapies and allogeneic stem cell transplantation, central nervous system (CNS) lymphomas and HIV, ATLL and gene therapy for malignant and nonmalignant hematologic disorders. Dr. Sica is a member of the Bone Marrow Transplant team at Montefiore.</p><p>Dr. Sica attended the University of Buenos Aires School of Medicine, where he received his Medical Degree. During his time there, he also served as an instructor of immunology, virology, pharmacology, and physical diagnosis. Dr. Sica began his postgraduate training with a residency in Internal Medicine at the Carney Hospital/Tufts University School of Medicine in Boston. Following this, he completed a fellowship in Hematology/Oncology at the University of Illinois at Chicago, where he received the E. Donnall Thomas Achievement in Medicine Award for his academic performance and the Edward Jenner Innovation in Medicine Award in recognition of his innovative contributions to the design of clinical protocols and trials. Later, he completed a fellowship in Blood and Marrow Transplant and Cellular Therapies at Stanford University. At that institution, he performed research with Dr. Sally Arai on Hodgkin's lymphoma using the Stanford-pioneered GN-BVC regimen (Gemcitabine, Vinorelbine-BCNU. Etoposide and Cyclophosphamide) which resulted in decreased toxicity and improved overall survival in patients. His work has been published in various review journals and abstracts.</p><p>Dr. Sica’s research focuses on novel cellular therapies, allogeneic bone marrow transplantation for malignant and nonmalignant hematologic disorders, and combination immunotherapy and cancer vaccine.</p><p>Dr. Sica is board certified in Internal Medicine, Hematology and Medical Oncology by the American Board of Internal Medicine.</p>
Jonathan M. Schwartz
<p>Jonathan M. Schwartz is a board Certified Transplant Hepatologist. He is a graduate of Tel Aviv University, Sackler School of Medicine. He was an Internal Medicine Resident at Albert Einstein College of Medicine and a Fellow in Gastroenterology/Transplant Hepatology at the University of Washington in Seattle. He returned to New York in 2011 from Portland, Oregon where he served as an Associate Professor of Medicine at Oregon Health and Sciences University.</p>
<p>Dr. Schwartz has an interest in treating patients with acute and chronic liver diseases including those patients with advanced liver diseases who require liver transplantation.</p>
<p>He has a special interest in the multidisciplinary care of patients with liver tumors.</p>
<p><strong><br /></strong></p>
<ul>
<li>Estes JD, Stolpman D, Olyaei A, Ham JM, <strong>Schwartz JM</strong>, Orloff SL. High Prevalence of Potentially Hepatotoxic Herbal Supplement Use in Fulminant Hepatic Failure Patients. Arch Surg. 2003;138(8):852-8.</li>
<li><strong>Schwartz JM</strong>, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman D, Kowdley KV. Cardiopulmonary Consequences of Transjugular Intrahepatic Portosystemic Shunts: Role of Increased Pulmonary Artery Pressure. J Clin Gastroenterol 2004;38(7):590-594.</li>
<li>Lim LL, Scarborough J, Thorne J, Graham E, Kempen J, Mackensen F, Nguyen Q D, Prabriputaloong T, Read R, Suhler EB, <strong>Schwartz JM</strong>, Smith JR. Uveitis in Patients with Autoimmune Hepatitis. Am J Ophthalmol. 2009;147(2):332-338.</li>
<li>O’Glasser AY, Scott DA, Corless CL, Zaman A, Sasaki A, Gopal DV, Rayhill SC, Orloff SL, Ham JM, Rabkin JM, Flora K, Davies CH, Broberg CS, and <strong>Schwartz JM.</strong>Hepatic and Cardiac Iron Overload Among Patients with End-Stage Liver Disease Referred for Liver Transplantation. Clinical Transplantation. Clin Transplant. 2010 Sep-Oct;24(5):643-51.</li>
<li>Kanwal F, Befeler A, Chari R, Marrero J, Kahn J, Afdhal N, Morgan T, Roberts L, Mohanty SR, <strong>Schwartz J</strong>, Van Thiel D, Hassanein TI, Li J, Zeringue A, DiBisceglie A. Rate of Potentially Curative Treatment in Patients with Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2012 Aug;36(3):257-65.</li>
<li>Bichoupan K1, <strong>Schwartz JM,</strong> Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H,Dieterich DT, Branch AD, Reinus JF. Effect of Fibrosis on Adverse Events in Patients with Hepatitis C Treated with Telaprevir. Aliment Pharmacol Ther. 2014;39(2):209-16.</li>
<li><strong>Schwartz J</strong> and Carithers RL. Epidemiology and Etiologic Associations of Primary Hepatocellular Carcinoma. In Rose BD, editor. Up to date in Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li><strong>Schwartz JM </strong>and Carithers RL, Jr. Clinical features, diagnosis, and screening for primary hepatocellular carcinoma. Up to date in Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Curley SA, Stewart KE, <strong>Schwartz JM</strong>, Carthers RL, Jr. Nonsurgical therapies for localized hepatocellular carcinoma. Up to date, Inc. Wellesley, MA, Updated 2014.<strong> </strong></li>
<li><strong>Schwartz JM</strong>. Approach to the patient with a focal liver lesion. Up to date Inc Gastroenterology and Hepatology. Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Hartwell L and <strong>Schwartz JM. </strong>AsymptomaticLiver Chemistry Abnormalities. Journal of Clinical Outcomes Management. 2009; 16 (11): 525-34.</li>
<li>Urquhart J<strong>, Schwartz, JM.</strong> Hepatocellular Carcinoma Surveillance in a Western Population with Hepatitis B. Current Hepatitis Reports, 2011.</li>
<li><strong>Schwartz, JM </strong>and Reinus JF. Prevalence and Natural History of Alcoholic Liver Disease. Clinics in Liver Disease. 2012; 16 (4): 659-66.</li>
</ul>
<p> </p>
Norman L. Rosen
Evelyn M. Rondinel
Samuel J. Rednor
Nephrology and Critical Care.
Dr. Rednor’s research focus is in acute kidney injury (AKI), cardiac arrest, and intubation.
<p>Samuel J. Rednor, DO, is Director of Wellness, Critical Care and Assistant Professor, Medicine at Montefiore Einstein. His clinical focus is nephrology and critical care.</p><p>After earning his Doctor of Osteopathic Medicine at Lake Erie College of Osteopathic Medicine in 2013, Dr. Rednor completed his residency in internal medicine at Southampton Hospital in 2016, where he was Chief Resident for one year. He then completed his renal fellowship at Montefiore in 2018, where he was Chief Renal Fellow during his last year. Dr. Rednor went on to complete an additional fellowship at Montefiore in critical care, which he completed in 2019.</p><p>Dr. Rednor’s research focus is in acute kidney injury (AKI), cardiac arrest, and intubation. His work has been published in peer-reviewed journals and he has given multiple lectures and presentations.</p><p>Dr. Rednor is board certified in Internal Medicine, Nephrology and Critical Care Medicine by the American Osteopathic Board of Internal Medicine. He is a member of the American Society of Nephrology (ASN), the American Osteopathic Association (AOA), the Society of Critical Care Medicine (SCCM) and the American College of Chest Physicians (CHEST). In 2018, Dr. Rednor won the Sharon R. Silbiger Teaching Award for excellence in teaching and in recognition as Outstanding Fellow of the Year from Einstein.</p>
Mark A. Ramirez
Stuart Packer
<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p>
<p>Dr. Packer’s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore’s Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p>
<p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer, Clinical Cancer Research, British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>
Dr. Packer’s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer.
<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p><p>Dr. Packer’s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore's Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p><p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer</em>, <em>Clinical Cancer Research</em>, <em>British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>